Navigation Links
Spondylitis in Medical Technology

SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

... arthritis (PsA) and severe, active ankylosing spondylitis (AS). Upon Commission approval in the ... arthritis, psoriatic arthritis and ankylosing spondylitis in the European Union," said Jerome A. Boscia, ... of their productive years. About Ankylosing spondylitis ...

Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis

... with psoriatic arthritis (PsA) and ankylosing spondylitis (AS). Investigators reported these new data from ... Go limumab - A R andomized Study in A nkylosing spondylitis Subjects of a Novel Anti-TNF mAB I njection ( S ... Improvements in the Assessment in Ankylosing spondylitis criteria (ASAS 20) were maintained through two ...

New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings

... six months as measured by the Bath Ankylosing spondylitis Functional Index (BASFI). Golimumab, Centocor ... the Golimumab - A Randomized Study in Ankylosing spondylitis Subjects of a Novel Anti-TNF mAB Injection ... defined as 40 percent improvement in ankylosing spondylitis signs and symptoms, compared with 15 percent of ...

CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients

... with polyarticular symmetrical subtypes of the disease. Ankylosing spondylitis Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. ...

New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients

... in adults, in combination with methotrexate; active psoriatic arthritis in adults, alone or in combination with methotrexate; and active ankylosing spondylitis in adults. Indications in Canada: In Canada, SIMPONI, in combination with methotrexate (MTX), is indicated for reducing the signs and ...

New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohn's Disease

... and dermatology. REMICADE has demonstrated broad clinical utility with indications in Crohn's disease (CD), rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), ulcerative colitis (UC), pediatric Crohn's disease (PCD) and psoriasis (PsO). The safety and efficacy of REMICADE ...

Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects

... a once-monthly subcutaneous anti-TNF agent for inflammatory and autoimmune disorders (under review in EU for rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, and in Phase III for ulcerative colitis); Schering-Plough has exclusive marketing rights to golimumab outside the U.S. ...

Continuous Treatment With Abbott's HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment

... is the only fully human monoclonal antibody approved for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), psoriasis, ankylosing spondylitis (AS), Crohn's disease and juvenile idiopathic arthritis (JIA) in the United States and Europe. HUMIRA resembles antibodies normally found in the ....

Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis

... with rheumatoid arthritis patients. It was approved for moderate to severe rheumatoid arthritis in 2002, psoriatic arthritis in 2005, ankylosing spondylitis in 2006, and moderate to severe Crohn's disease in 2007. "The approval of HUMIRA for psoriasis is welcome news for people living with this ...

Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)

... of Amgen, manufactures ENBREL, which may be used to treat rheumatoid arthritis, junior rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and psoriasis. Additional information about ENBREL, including the full U.S. Prescribing Information, can be found on the Web site sponsored by the ...

Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis

... 100 mg group) of study subjects presented with enthesitis (at least one tender body enthesitis site) as measured by the Maastricht Ankylosing spondylitis Enthesitis Score (MASES) index modified for Psoriatic Arthritis; 34 percent (placebo group), 34 percent (golimumab 50 mg group) and 34 percent ...

Remicade Two Year Data in Ankylosing Spondylitis Show Improvement in Spinal Mobility and Spinal Inflammation

... Rheumatology showed that patients with ankylosing spondylitis (AS) who received REMICADE(R) (infliximab) over ... 279 patients with AS as part of the Ankylosing spondylitis Study for the Evaluation of Recombinant ... study utilized the Bath Ankylosing spondylitis Metrology Index (BASMI) and chest expansion ...

Trexima (Sumatriptan/Naproxen Sodium) Superior Efficacy Data Published in JAMA

... and in a number of over-the-counter medications. Naproxen sodium is indicated for the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and juvenile arthritis. It is also indicated for the treatment of tendonitis, bursitis, acute gout and for the management of pain and primary ...

Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Efficacy Across Multiple Migraine Attacks

... and in a number of over-the-counter medications. Naproxen sodium is indicated for the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and juvenile arthritis. It is also indicated for the treatment of tendinitis, bursitis, acute gout and for the management of pain and primary ...

Trexima (Sumatriptan/Naproxen Sodium) Provided Relief of Both Traditional and Non-traditional Migraine Symptoms

... and in a number of over-the-counter medications. Naproxen sodium is indicated for the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and juvenile arthritis. It is also indicated for the treatment of tendinitis, bursitis, acute gout and for the management of pain and primary ...

New Analysis of Data Shows Treatment With Abbott's Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohn's Disease

... HUMIRA is the only fully human monoclonal antibody approved for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS, an arthritis of the spine) in the U.S. and Europe, and the only fully human monoclonal antibody approved for Crohn's disease in the U.S. HUMIRA ...

Long-Term Extension of Ulcerative Colitis Study Shows Remicade Responders Maintained Improvement Through Two Years of Follow-Up

... rheumatology and dermatology. REMICADE has demonstrated broad clinical utility in Crohn's disease (CD), rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), ulcerative colitis (UC), pediatric Crohn's disease (PCD) and psoriasis (PsO). The safety and efficacy of REMICADE ...

Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free Response Across Multiple Attacks

... and in a number of over-the-counter medications. Naproxen sodium is indicated for the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and juvenile arthritis. It is also indicated for the treatment of tendinitis, bursitis, acute gout and for the management of pain and primary ...

Three Studies Suggest Abbott's Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis

... HUMIRA is the only fully human monoclonal antibody approved for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS, an arthritis of the spine) and Crohn's disease in the U.S. and Europe. HUMIRA resembles antibodies normally found in the body. It works by ...
Other Contents
(Date:2/24/2015)... 24, 2015 Research and Markets ... the "Global 2D Gesture Recognition Market 2015-2019" ... The analysts forecast the Global 2D Gesture Recognition ... over the period 2014-2019 The increased ... is one of the major trends in the ...
(Date:2/12/2015)... , Feb. 12, 2015   MedNet Solutions ... in clinical study management systems, has recently bolstered ... further distinguishing iMedNet as ... Organizations (CROs) and healthcare consultants.  Building on the ... customer referrals and numerous co-marketing opportunities), MedNet,s new ...
(Date:2/5/2015)... PARK, North Carolina , 5. Februar ... 35. Jahr als spezialisiertes Logistikunternehmen und hat ... als einzige klinische Logistikfirma (Clinical Logistics Organization ... Kernbotschaft der neuen Kampagne lautet First ... Lieferungen. Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
Breaking Biology News(10 mins):Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3
(Date:2/27/2015)... Rafael, CA (PRWEB) February 27, 2015 The ... provide campers with newer facilities and to make camp more ... a better location for a Contact Football Camp. The fields ... the best in the country,” states Mike de Surville, vice ... our staff is comprised of experienced coaches with the passion ...
(Date:2/27/2015)... February 27, 2015 RDI-Engineering will be ... Pi Day event on March 14, at Moreno Valley ... demonstrations on how to use engineering software and tools, ... be hosted by Moreno Valley College’s Upward Bound Math ... Center (SSC) in hopes to encourage students to seek ...
(Date:2/27/2015)... 27, 2015 Is it reasonable – and ... practices and games, and possible to do so without causing ... sports might be at high risk for concern and could ... the issues being addressed by two introductory bills, Int. ... hearing last month in New York City. More specifically, ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Many ... for people’s health. Mercola.com has introduced organic cotton ... contain toxic flame retardant chemicals. Dr. Mercola’s Healthy ... design and better materials. Organic cotton is significantly ... Mercola’s organic bedding products are made by Naturepedic ...
(Date:2/27/2015)... 2015 According to a Feb. 12, ... drug used to treat cancer by killing cancer stem cells, ... Drug Administration (FDA) for use in the treatment of mesothelioma.* ... the FDA to encourage the development of drugs for the ... about the FDA’s decision,” said Melinda Helbock, Founder of The ...
Breaking Medicine News(10 mins):Health News:US Sports Camps Football Camps Announce New Contact Football Camp Northeast Location 2Health News:RDI-Engineering Participates in STEM”U”LATE Your Mind Event to Host Educational Exhibition 2Health News:NYSATA Athletic Trainers Provide Expert Testimony at NYC Youth Concussion and Sports Safety Hearing 2Health News:NYSATA Athletic Trainers Provide Expert Testimony at NYC Youth Concussion and Sports Safety Hearing 3Health News:New Drug Receives FDA Approval as Orphan Drug for the Treatment of Mesothelioma 2Health News:New Drug Receives FDA Approval as Orphan Drug for the Treatment of Mesothelioma 3
Other TagsOther Tags